Following a directed appraisal
AWMSG advice |
|||
| Status: Recommended | |||
Galsulfase (Naglazyme®) is recommended as an option for use within NHS Wales for the treatment of patients with long term enzyme replacement therapy in mucopolysaccharidosis VI (N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome). |
|||
|
|||
Medicine details |
|||
| Medicine name | galsulfase (Naglazyme®) | ||
| Formulation | 1 mg/ml concentrate for solution for infusion | ||
| Reference number | 155 | ||
| Indication | Treatment of long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome) |
||
| Company | BioMarin Europe Ltd | ||
| BNF chapter | Nutrition & blood | ||
| Submission type | Directed | ||
| Status | Recommended | ||
| Advice number | 0524 | ||
| AWMSG meeting date | 08/10/2024 | ||
| Date of issue | 09/10/2024 | ||